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A B S T R A C T
In the north Croatian Adriatic area in the period of seven years (from January 2001 to September 2007) 475 patients
(39 to 80 years of age) with dry form of age related macular degeneration (AMD) were diagnosed. Complete ophthalmolo-
gic examination with special reference to visual field testing (Perimetric analysis) was performed. Peripheral visual field
defects were found in 85% of patients. Elderly patients with more advanced forms of macular degeneration had more pe-
ripheral visual field defects. In 400 patients corticosteroid therapy (5 mg Prednisolonacetate, anterior H-inject, Win-
thorp) was administered via parabulbar injections every day/five days. Control group consisted of 75 patients treated
with regular polyvitamine therapy (Lutein, Beta Karoten, Vitamin E). Patients treated with corticosteroids had periphe-
ral visual field improvements from 10 to 25 degrees and central field improvements from 5 to 20 %. In the control group
treated with vitamins, central visual field showed improvements from 0.5 to 1% in 43 patients but without peripheral vi-
sual field improvements after 6 months.
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Introduction
Age related macular degeneration (AMD) is one of the
world leading causes of visual impairment in developed
countries today. In advanced stages visual function is af-
fected and may lead to macular blindness. Macular dege-
neration was considered as »central visual disease« or
»macular disease«. Some recent publications are giving
new insight to this disease, proposing that AMD is both
central and peripheral neurosensory retinal disease1,2
and Ethan et al. in 2006 confirmed that hypothesis by
proteomic analysis of the macular and peripheral neuro-
sensory retina3.
It is well known that different meteorological factors
can influence on humans4–12. Special risk factors affect-
ing eye status are ultraviolet A and B rays and »blue
light«. Exposure to sunlight during summer in coast
areas may lead to retinal photo-toxicity. Therapeutic ap-
proach to AMD varies, but most authors use similar
agents13–18. Some authors use corticosteroids in the
treatment of dry macular degeneration19. The main topic
of this paper is steroid treatment of age related macular
degeneration with special reference to peripheral visual
field improvements.
Patients and Methods
In 475 patients with dry form of macular degenera-
tion special attention was dedicated to peripheral visual
field analysis (Kowa perimeter) before and after finish-
ing therapy. Patients were divided in two groups: the first
group of 400 patients received five daily doses of 5 mg of
Prednisolone acetate (anterior H-inject, Winthorp, Lich-
tenstein) in parabulbar injections. The second group of
75 patients was a control group and received multivita-
min therapy (Lutein, Beta Karoten, Vitamin E) in ordi-
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nary doses. Visual acuity, visual field, intraocular pres-
sure, biomicroscopic and fundus examination were
performed before therapy, after first month and after 6
months of therapy.
Results
The first group of patients with parabulbar corticoste-
roid treatment gained peripheral visual field improve-
ment from 10 to 25% and central improvement of 5 to
20%. In the control group there was a central improve-
ment of 0.5 to 1 % in 43 patients but with no significant
peripheral visual field improvement. Typical peripheral
isopteres before and after therapy with steroids are
shown on Figure 1. Sharp defects of visual field are dimi-
nishing after steroid therapy. »Meridian thresholds« of
isoptere number 1 show the situation before therapy and
isoptere number 2 show stimulus for central macula and
periphery up to 35 degree.
Discussion and Conclusion
This large study with respective clinical material has
shown that dry form of age related senile macular degen-
eration affects not only macular area. Peripheral neuro-
sensory retina is very often affected. Central visual acu-
ity in macular degeneration can be altered with certain
vitamin therapy, especially vitamin E as an antioxidant.
This effect on peripheral vision is minimal. Steroids
(Prednisolone acetate) have significant impact not only
on central visual acuity but also on peripheral vision.
Dry forms of age related macular degeneration affects
entire neurosensory retina. It is very important to perfo-
rm visual field exam as a standard adjunct to ophthalmo-
logical examination. Prednisolone acetate is a drug of
choice in the treatment and prevention of dry macular
degeneration which is a very serious problem in develo-
ped countries.
B. Vojnikovi} et al.: Age-Related Macular Degeneration Therapy with Prednisolone Acetate, Coll. Antropol. 32 (2008) 2: 351–353
352
Fig. 1. Visual field before and after therapy with Prednisolone acetate (1A and 2A before; 1B and 2B after therapy).
Fig. 2. Meridian threshold before and after therapy with Prednisolone acetate (1 before and 2 after therapy).
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DUGOGODI[NJA STUDIJA TERAPIJE SENILNE MAKULARNE DEGENERACIJE PREDNISOLON
ACETATOM, S POSEBNIM OSVRTOM NA PERIFERNI VID
S A @ E T A K
U periodu od 2001. do 2008. godine dijagnosticirali smo na podru~ju sjevernog hrvatskog primorja 475 slu~ajeva se-
nilne makularne degeneracije (SMD), u dobi pacijenata od 39 do 80 godina. Pored rutinske oftalmolo{ke pretrage, po-
sebna se pa`nja posvetila perifernom vidu. Defekt perifernog vida dijagnosticiran je u 85% pacijenata. [to su pacijenti
bili stariji i makularna degeneracija ja~e uznapredovala, to je bio ja~i defekt periferije vida. U 400 pacijenata primijenje-
na je terapija preparatom Prednisolone acetate (Predni H injekt, Winthrop, Lichtenstein), s 5 mg parabulbarno obos-
trano, svakog dana kroz 5 dana. Kontrolna skupina od 75 pacijenata tretirana je uobi~ajenom terapijom vitaminima za
o~i (Lutein, Beta Karoten, Vitamin E) u uobi~ajenim dozama. U svih 400 bolesnika tretiranih sa Predni H injekt, do{lo
je do vidljivog pro{irenja periferije vidnog polja za 10 do 25 stupnjeva, pored pobolj{anja centralnog vida za 5 do 20%. U
kontrolnoj skupini tretiranoj vitaminima za o~i, pobolj{ao se centralni vid za 0,5 do 1% u 43 slu~ajeva, ali bez pobolj{a-
nja periferije, nakon tretmana od 6 mjeseci.
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